These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

103 related items for PubMed ID: 10440070

  • 1. An evaluation of susceptibility testing methods for ampicillin-sulbactam using a panel of beta-lactamase-producing bacteria.
    Siu LK, Lo JY, Cheng WL, Ho PL, Ng WS, Chau PY.
    APMIS; 1999 Jul; 107(7):703-8. PubMed ID: 10440070
    [Abstract] [Full Text] [Related]

  • 2. Correlation of in vitro susceptibility testing results for amoxicillin-clavulanate and ampicillin-sulbactam using a panel of beta-lactamase-producing Enterobacteriaceae.
    Siu LK, Cheng WL, Ho PL, Ng WS, Chau PY, Lo JY.
    APMIS; 1998 Sep; 106(9):917-20. PubMed ID: 9808419
    [Abstract] [Full Text] [Related]

  • 3. Piperacillin tazobactam compared with co-amoxiclav, ampicillin plus sulbactam and timentin against beta-lactamase-producing clinical isolates of Escherichia coli, Klebsiella pneumoniae and Klebsiella oxytoca.
    Traub WH, Leonhard B.
    Chemotherapy; 1995 Sep; 41(5):345-52. PubMed ID: 8521736
    [Abstract] [Full Text] [Related]

  • 4. Ampicillin-sulbactam and amoxicillin-clavulanate susceptibility testing of Escherichia coli isolates with different beta-lactam resistance phenotypes.
    Oliver A, Pérez-Vázquez M, Martínez-Ferrer M, Baquero F, De Rafael L, Cantón R.
    Antimicrob Agents Chemother; 1999 Apr; 43(4):862-7. PubMed ID: 10103192
    [Abstract] [Full Text] [Related]

  • 5. Comparative in vitro activities of amoxicillin-clavulanate, ampicillin-sulbactam and piperacillin-tazobactam against strains of Escherichia coli and proteus mirabilis harbouring known beta-lactamases.
    Gatermann S, Marre R.
    Infection; 1991 Apr; 19(2):106-9. PubMed ID: 1646771
    [Abstract] [Full Text] [Related]

  • 6. Role of TEM-1 β-Lactamase in the Predominance of Ampicillin-Sulbactam-Nonsusceptible Escherichia coli in Japan.
    Noguchi T, Matsumura Y, Kanahashi T, Tanaka M, Tsuchido Y, Matsumura T, Nakano S, Yamamoto M, Nagao M, Ichiyama S.
    Antimicrob Agents Chemother; 2019 Feb; 63(2):. PubMed ID: 30455244
    [Abstract] [Full Text] [Related]

  • 7. Use of a predictor panel to evaluate susceptibility testing methods for ampicillin-sulbactam.
    Bradford PA, Sanders CC.
    Antimicrob Agents Chemother; 1993 Feb; 37(2):251-9. PubMed ID: 8452355
    [Abstract] [Full Text] [Related]

  • 8. In vitro activity of sulbactam/ampicillin against ampicillin-resistant, beta-lactamase-producing bacteria isolated in Italian hospitals.
    Varaldo PE, Ripa S, Nicoletti G, Covelli I, Satta G, Carlone N, Fontana R.
    Chemotherapy; 1990 Feb; 36(2):141-6. PubMed ID: 2178890
    [Abstract] [Full Text] [Related]

  • 9. [Errors of the agar diffusion method to predict Escherichia coli's susceptibility to ampicillin-sulbactam and amoxicillin-clavulanic acid].
    Villar HE, Jugo MB, Fernández-Lausi A, Farinati AE.
    Enferm Infecc Microbiol Clin; 1996 May; 14(5):308-10. PubMed ID: 8744371
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Escherichia coli resistant to ampicillin/sulbactam.
    Eng RH, Yen K, Smith SM, Citron DM, Goldstein EJ, Greenberg R, Cherubin CE.
    Chemotherapy; 1992 May; 38(6):399-404. PubMed ID: 1288964
    [Abstract] [Full Text] [Related]

  • 15. The cefoperazone-sulbactam combination. In vitro qualities including beta-lactamase stability, antimicrobial activity, and interpretive criteria for disk diffusion tests.
    Jones RN, Barry AL, Thornsberry C, Wilson HW.
    Am J Clin Pathol; 1985 Oct; 84(4):496-504. PubMed ID: 2994461
    [Abstract] [Full Text] [Related]

  • 16. An in-vitro and in-vivo comparison of the activity of beta-lactamase inhibitor combinations with imipenem and cephalosporins against Escherichia coli producing TEM-1 or TEM-2 beta-lactamase.
    Cherubin CE, Eng RH, Smith SM, Tan EN.
    J Antimicrob Chemother; 1991 Jul; 28(1):61-70. PubMed ID: 1769944
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. beta-Lactam resistance phenotype determination in Escherichia coli isolates from University Malaya Medical Centre.
    Wong JS, Mohd Azri ZA, Subramaniam G, Ho SE, Palasubramaniam S, Navaratnam P.
    Malays J Pathol; 2003 Dec; 25(2):113-9. PubMed ID: 16196367
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.